Liver/Biliary Disorders News

Sodium-glucose cotransporter 2 inhibitors were associated with a higher likelihood of disease regression among patients with concomitant metabolic dysfunction-associated steatotic liver disease and type 2 diabetes, data showed.

A “rapid response to hepatitis A exposure” helped minimize the risk for transmission and prevent an HAV outbreak among incarcerated persons in a Los Angeles County jail, according to an investigation in Morbidity and Mortality Weekly Report.

Researchers have estimated that annual costs associated with alcohol-associated liver disease will climb from $31 billion in 2022 to $66 billion in 2040 — a 118% increase — with costs among women accounting for 43% of the total expenditure.

A “vast majority” of liver transplant centers use stigmatizing language, such as “alcoholic” or “alcohol abuse,” when describing patients with alcohol use disorder and alcohol-associated liver disease on their websites, researchers reported.

Resmetirom 80 mg and 100 mg outperformed placebo in disease resolution and improvement in liver fibrosis among patients with metabolic dysfunction-associated steatohepatitis, according to 52-week results from the MAESTRO-NASH trial.

Topline findings from a phase 2 trial showed that survodutide achieved “statistically significant improvement” for metabolic dysfunction-associated steatohepatitis and liver fibrosis in 83% of patients, Boehringer Ingelheim announced.

Around 17% of patients with metabolic dysfunction-associated steatotic liver disease have or will be diagnosed with alcohol-related disease, which research shows is associated with a threefold higher rate of developing cirrhosis or cancer.

Increased intake of dietary niacin may reduce the risk for all-cause mortality but not cardiovascular disease-related mortality among patients with metabolic dysfunction-associated steatotic liver disease, data showed.

An analysis of ED utilization from 2016 to 2019 revealed an increase in visits for alcohol-associated hepatitis, particularly among patients aged 25 to 44 years, as well as an increase in disease severity.

In a Healio video exclusive, Edward V. Loftus Jr., MD, urged gastroenterologists to familiarize themselves with a “four-pronged approach to liver disease” ahead of the critical shortage of U.S. hepatologists expected by 2033.